CoMentis, Inc. is focused on developing drugs to treat various central nervous system disorders such as Alzheimer’s disease and schizophrenia. We cover the research and development spectrum from initial drug design through manufacturing and clinical trials.

CoMentis is approaching the treatment of central nervous system disorders from many angles. These approaches include BACE inhibitors for the treatment of Alzheimer’s disease and modulators of the α7 nicotinic acetylcholine receptor (nAChR) for the treatment of schizophrenia and other CNS disorders.